New data from the CONFIDENCE trial demonstrates that combination therapy with finerenone and empagliflozin leads to ...

The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

Patients with diabetic kidney disease (DKD) and anemia have no worse, and possibly better, cardiovascular outcomes from finerenone treatment.

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

A major international study presented at the 62nd ERA Congress reveals that the long-accepted survival advantage of ...